Actinic keratoses: the bald facts

1996 ◽  
Vol 132 (9) ◽  
pp. 1132-1133 ◽  
Author(s):  
C. C. Long
Keyword(s):  
Actinic Keratoses

Actinic Keratoses: Reclassification Spurs Debate

2007 ◽  
Vol 38 (10) ◽  
pp. 25
Author(s):  
BRUCE JANCIN
Keyword(s):  
Actinic Keratoses

Australian Study Shows High Turnover of Actinic Keratoses

2007 ◽  
Vol 38 (10) ◽  
pp. 25
Author(s):  
BRUCE JANCIN
Keyword(s):  
Australian Study ◽  
High Turnover ◽  
Actinic Keratoses

Location Should Drive PDT Protocol for Actinic Keratoses

2011 ◽  
Vol 42 (3) ◽  
pp. 18
Author(s):  
HEIDI SPLETE
Keyword(s):  
Actinic Keratoses

Two Strengths of Picato Gel Okayed for Actinic Keratoses

2012 ◽  
Vol 43 (3) ◽  
pp. 10
Author(s):  
EMILY HAYES
Keyword(s):  
Actinic Keratoses

Topical Fluorouracil for Actinic Keratoses and Photoaging: A Clinical and Molecular Analysis

2010 ◽  
Vol 2010 ◽  
pp. 476-477
Author(s):  
G.K. Kim ◽  
J.Q. Del Rosso
Keyword(s):  
Molecular Analysis ◽  
Actinic Keratoses

Selectivity of fluorouracil in treatment of actinic keratoses

1968 ◽  
Vol 98 (2) ◽  
pp. 166-167
Author(s):  
E. I. Saltzer
Keyword(s):  
Actinic Keratoses

Actinic keratoses: when and how to treat a single lesion

2020 ◽  
Vol 155 (4) ◽  
Author(s):  
Anna Carbone ◽  
Vitaliano Silipo ◽  
Laura Eibenschutz ◽  
Paolo Piemonte ◽  
Angela Ferrari ◽  
...  
Keyword(s):  
Actinic Keratoses ◽  
Single Lesion

Do Second-Time Users of Topical Imiquimod have a More Rapid Onset of Clinical Response?

2018 ◽  
Vol 2 (3) ◽  
pp. 156-161
Author(s):  
Stacy L McMurray ◽  
Matthew Reynolds ◽  
Matthew S Dinehart ◽  
Scott M Dinehart
Keyword(s):  
Clinical Response ◽  
Time Use ◽  
Γδ T Cells ◽  
Rapid Onset ◽  
Primary Objective ◽  
Imiquimod Cream ◽  
Actinic Keratoses ◽  
Topical Imiquimod ◽  
Primary Endpoints ◽  
Time To Onset

Introduction: Topical imiquimod is commonly used in dermatology for treatment of actinic keratoses (AK). Prior studies in humans and mice have suggested the potential for immune recall with imiquimod based on higher degrees of AK clearance and activation of memory γδ T-cells in a mouse model. Anecdotal reports suggest a more rapid time-to-onset of clinical response with second time use of imiquimod. However, the potential for immune recall demonstrated by time-to-onset of clinical response has not been formally investigated.Objective:  The primary objective of this study was to determine if there is a difference in time-to-onset of clinical response between naïve and prior users of topical imiquimod for the treatment of actinic keratoses.Methods:  A total of 92 patients were treated with 5% imiquimod cream for actinic keratoses of the head and neck. Patients were instructed to apply 5% imiquimod cream to the affected areas once daily until reaching a therapeutic endpoint of crusting/scabbing. The primary endpoints in the study were time (days) to onset of erythema and time to onset of crusting/scabbing. Results were self-reported.Results:  The average time (days) to onset of erythema was 5.48 ± 3.19 days in naïve users and 4.7 ± 2.91 days in prior users (p= 0.22). Average time to onset of crusting/scabbing was 9.2 ± 4.34 days in naïve users and 9.02 ± 3.65 days in prior users (p=0.35).Conclusion:  Our study revealed there is no difference in time-to-onset of erythema or scabbing/crusting with second-time use of imiquimod.  While immune recall may be possible with use of imiquimod, the results of this study indicate that it may be independent of time-to-onset of clinical response.  

Sign in / Sign up

Export Citation Format

Share Document